New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women receiving endocrine therapy for hormone receptor (HR)-positive breast cancer or ...

This was followed by Merck & Co’s Keytruda (pembrolizumab) and a gang of rival PD-L/PD-L1 checkpoint inhibitors, which have set new standards in cancer care in many different forms of the disease.

BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug ...

UBS upgraded Alkermes (NASDAQ: ALKS) from Neutral to Buy on Tuesday, raising its price target to $42.00 from $33.00. The upgrade reflects UBS’s growing confidence in the company’s orexin ...

About Centessa’s Orexin Receptor 2 (OX2R) Agonist Program Orexin is a neuropeptide that regulates the sleep-wake cycle, leading to arousal and promoting wakefulness.

Issue: Whether, if a pharmaceutical manufacturer fully informs the Food & Drug Administration of all material information bearing on a drug’s potential risk and seeks approval to warn of that risk on ...

BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration ...

Analyst Ratings Published 06/17/2025, 05:14 AM 0 UBS upgrades Alkermes stock rating on orexin treatment potential ALKS -1.53% ...

BOSTON and LONDON, June 16, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today anno ...

Lucey found that suvorexant, a different dual orexin receptor antagonist, reduced p-tau181 in CSF of healthy volunteers, aged 45-65 (Lucey et al., 2023). “Since suvorexant did not increase sleep ...